Pluriomics Stem Cell technology

Past User Meeting

Combining Pluricyte® Cardiomyocytes & MEA for Safety Pharmacology applications 

November 24-25, 2016 – Leiden, The Netherlands

 

Introduction

Pluriomics’ User Meeting brought together experts in stem cell biology and pharmaceutical development to present and discuss opportunities for combining hiPSC-cardiomyocytes and MEA technologies in drug and chemical safety testing.  Taking place at Pluriomics our User Meeting combined  a plenary session chaired by Jean-Pierre Valentin (UCB) and MEA live demos including:

o   xCELLigence ® RTCA Cardio instrument (ACEA Biosciences)

o   Maestro multiwell 768-channel MEA platform (Axion BioSystems)

o   Multiwell MEA System (Multi Channel Systems)

o   CardioExcyte 96 (Nanion Technologies)

 

Pluriomics User meeting was a great opportunity to learn more about the added value of Pluricyte® Cardiomyocytes, MEA and Safety Pharmacology applications, to share your experience with other users, to exchange with experts and to improve technical knowledge.

 

Agenda

Thursday November 24th, 2016

13:30

Arrival at Pluriomics – Coffee & Registration

14:00

Welcoming message, Stefan Braam, CEO, Pluriomics

14:15

Demonstrations

  • Pluricyte® Cardiomyocytes in combination with Axion Maestro multiwell 768-channel MEA platform
  • Pluricyte® Cardiomyocytes in combination with ACEA xCELLigence® RTCA CardioECR

15:45

Coffee Break & Networking

16:15

Demonstrations

  • Pluricyte® Cardiomyocytes in combination with Axion Maestro multiwell 768-channel MEA platform
  • Pluricyte® Cardiomyocytes in combination with ACEA xCELLigence® RTCA CardioECR

17:45

End of the demonstrations

19:30

Dinner & Networking

 
Friday November 25th, 2016

8:30

Arrival at Pluriomics – Coffee & Registration

8:50

Welcoming message, Stefan Braam, CEO, Pluriomics

 

9:00

Plenary session – Predictive toxicology & Safety

Chairman: Jean-Pierre Valentin, Senior Director, Head of Investigative Toxicology, UCB Biopharma SPRL

  • Pluricyte® Cardiomyocytes as a predictive tool for preclinical safety assessment, Marijn Vlaming, VP Technology, Pluriomics
  • Pluriomics hiPS Cardiomyocytes in Drug and Toxicity Screening Applications, Elena Dragicevic, Senior Scientist / Product Manager Axion Product Family, Nanion Technologies GmbH
  • Pluricyte® ventricular cardiomyocytes as a predictive tool for preclinical safety assessment, comparison with isolated guinea-pig ventricular cardiomyocytes, Richard Printemps, Head of the Patch-Clamp Laboratory, PhysioStim

10:30

Coffee Break & Networking

11:00

  • Assessment of electrophysiology, contractility and viability effects of three UCB compounds in hiPSC-derived cardiomyocytes using the RTCA CardioECR platform, Tessa de Korte, Application Specialist, Pluriomics
  • Influence of Cell Density on the Evaluation of Pharmacological Test Compounds Using MEA Technology, Udo Kraushaar, Head of Electrophysiology, NMI

12:00

Lunch & Networking

13:00

Demonstrations

  • Pluricyte® Cardiomyocytes in combination with Multiwell-MEA System from Multi Channel Systems
  • Pluricyte® Cardiomyocytes in combination with Nanion CardioExcyte 96

14:30

Coffee Break & Networking

15:00

 

Demonstrations

  • Pluricyte® Cardiomyocytes in combination with Multiwell-MEA System from Multi Channel Systems
  • Pluricyte® Cardiomyocytes in combination with Nanion CardioExcyte 96

16:30

End of the User Meeting